313 related articles for article (PubMed ID: 22847491)
1. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
Pandey R; Kochar R
J Gastrointest Cancer; 2012 Dec; 43(4):547-52. PubMed ID: 22847491
[TBL] [Abstract][Full Text] [Related]
2. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.
Tirumani SH; Shinagare AB; Jagannathan JP; Krajewski KM; Ramaiya NH; Raut CP
Eur J Surg Oncol; 2014 Apr; 40(4):420-8. PubMed ID: 24238762
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal stromal tumors: case series of 29 patients defining the role of imatinib prior to surgery.
Shrikhande SV; Marda SS; Suradkar K; Arya S; Shetty GS; Bal M; Shukla PJ; Goel M; Mohandas KM
World J Surg; 2012 Apr; 36(4):864-71. PubMed ID: 22350473
[TBL] [Abstract][Full Text] [Related]
4. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
5. [Gastrointestinal stromal tumours bigger than 20 cm: experience with imatinib chemotherapy in neoadjuvant intention].
Girotti P; Rolinger J; Kopp HG; Königsrainer A; Ladurner R
Z Gastroenterol; 2014 Jan; 52(1):50-4. PubMed ID: 24420799
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
7. The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction.
Staiger WI; Ronellenfitsch U; Kaehler G; Schildhaus HU; Dimitrakopoulou-Strauss A; Schwarzbach MH; Hohenberger P
World J Surg Oncol; 2008 Apr; 6():37. PubMed ID: 18394167
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant and adjuvant therapy with imatinib for locally advanced gastrointestinal stromal tumors in eastern Indian patients.
Ashraf M; Jha J; Choudhry A; Aggarwal B; Nayak S; Chakraborty J; Majumder S; Biswas J
Asian Pac J Cancer Prev; 2011; 12(8):2059-64. PubMed ID: 22292651
[TBL] [Abstract][Full Text] [Related]
9. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors: who should get imatinib and for how long?
Balachandran VP; DeMatteo RP
Adv Surg; 2014; 48(1):165-83. PubMed ID: 25293614
[TBL] [Abstract][Full Text] [Related]
11. Combined Therapy of Gastrointestinal Stromal Tumors.
Rutkowski P; Hompes D
Surg Oncol Clin N Am; 2016 Oct; 25(4):735-59. PubMed ID: 27591496
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
[TBL] [Abstract][Full Text] [Related]
13. The role of surgery in the multidisciplinary management of patients with localized gastrointestinal stromal tumors.
Bednarski BK; Pisters PW; Hunt KK
Expert Rev Anticancer Ther; 2012 Aug; 12(8):1069-78. PubMed ID: 23030225
[TBL] [Abstract][Full Text] [Related]
14. Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor.
Shen C; Chen H; Yin Y; Chen J; Zhang B; Chen Z; Chen J
Clinics (Sao Paulo); 2014 Nov; 69(11):758-62. PubMed ID: 25518034
[TBL] [Abstract][Full Text] [Related]
15. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
16. Multidisciplinary care of gastrointestinal stromal tumour: a review and a proposal for a pre-treatment classification.
Cananzi FC; Judson I; Lorenzi B; Benson C; Mudan S
Eur J Surg Oncol; 2013 Nov; 39(11):1171-8. PubMed ID: 24063969
[TBL] [Abstract][Full Text] [Related]
17. Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors.
Sicklick JK; Lopez NE
J Gastrointest Surg; 2013 Nov; 17(11):1997-2006. PubMed ID: 23775094
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors.
Eisenberg BL; Trent JC
Int J Cancer; 2011 Dec; 129(11):2533-42. PubMed ID: 21671474
[TBL] [Abstract][Full Text] [Related]
19. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
20. Updates on the management of gastrointestinal stromal tumors.
Bamboat ZM; Dematteo RP
Surg Oncol Clin N Am; 2012 Apr; 21(2):301-16. PubMed ID: 22365521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
